株式会社ユカリア Logo

株式会社ユカリア

Management, DX, and data solutions for healthcare and long-term care providers.

286A | T

Overview

Corporate Details

ISIN(s):
JP3946900002
LEI:
Country:
Japan
Address:
千代田区霞が関3丁目2番5号 霞が関ビルディング19階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Eucalia Inc. is a healthcare services company dedicated to transforming the medical and long-term care sectors. Its core business is providing management and operational support for hospitals and care facilities. The company offers a comprehensive suite of services, including management consulting, medical digital transformation (DX) solutions, and medical data utilization. Eucalia also directly operates facilities for the elderly. Its client base includes hospitals, care facilities, pharmaceutical companies, and academic institutions. The company operates on the principle of 'Sanpo-yoshi' (good for all three parties), aiming to build a sustainable ecosystem that improves the quality of life for facility management, healthcare workers, and patients alike, thereby strengthening the social infrastructure of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 09:21
Interim Report
確認書
Japanese 8.6 KB
2025-08-14 09:19
Interim Report
半期報告書-第21期(2025/01/01-2025/12/31)
Japanese 295.4 KB
2025-06-18 02:30
M&A Activity
臨時報告書
Japanese 20.2 KB
2025-06-05 09:46
M&A Activity
臨時報告書
Japanese 32.5 KB
2025-05-15 09:01
M&A Activity
臨時報告書
Japanese 30.0 KB
2025-05-15 07:43
M&A Activity
臨時報告書
Japanese 29.9 KB
2025-03-28 06:37
Post-Annual General Meeting Information
臨時報告書
Japanese 25.3 KB
2025-03-28 06:36
Registration Form
確認書
Japanese 8.6 KB
2025-03-28 06:36
Governance Information
内部統制報告書-第20期(2024/01/01-2024/12/31)
Japanese 23.3 KB
2025-03-28 06:35
Annual Report
有価証券報告書-第20期(2024/01/01-2024/12/31)
Japanese 2.0 MB
2025-02-17 02:05
M&A Activity
臨時報告書
Japanese 27.0 KB
2024-12-03 07:30
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.1 MB
2024-11-25 07:30
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.1 MB
2024-11-08 07:30
Registration Form
有価証券届出書(新規公開時)
Japanese 4.0 MB
2024-03-29 07:00
Foreign Filer Report
親会社等状況報告書(内国会社)-第19期(2023/01/01-2023/12/31)
Japanese 25.1 KB

Automate Your Workflow. Get a real-time feed of all 株式会社ユカリア filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社ユカリア

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社ユカリア via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.